The wound care biologics market was valued at $1.8 billion in 2022 and is estimated to reach $3.3 billion by 2032, exhibiting a CAGR of 6.1% from 2023 to 2032. Wound care biologics refers to a category of advanced medical products that are derived from biological sources or manufactured using biotechnology processes. These wound care biologics products are designed for healing and management of various types of wounds, such as acute and chronic wounds. In addition, wound care biologics products consist of extracellular matrix, growth factors, cellular components, or skin substitutes that mimic or supplement the body's natural healing processes. Biologic products such as biological skin substitutes and topical agents are used in the wound healing process by tissue regeneration and by reducing inflammation.
The wound care biologics market has experienced significant growth owing to the increase in prevalence of chronic wounds, such as diabetic foot ulcers, venous leg ulcers, and pressure ulcers, which is a major factor that fosters the wound care biologics market growth. For instance, according to National Diabetes Statistics Report by Centers for Disease Control and Prevention (CDC), 2022, about 37.3 million people are diabetic in the U.S. As the number of people with diabetes continues to grow, so does the risk of developing diabetic foot ulcers, leading to higher demand for effective treatment options including wound care biologics.
In addition, elderly individuals are more prone to chronic wounds thus, the rise in geriatric population drives the demand for wound care biologics and propels market growth. These advanced therapies provide efficient wound healing to this vulnerable population. Moreover, traditional wound care products such as hydrocolloids, hydrogels, film & foam dressings, and alginates are being increasingly replaced with advanced wound care products such as biologics, due to their enhanced effectiveness in managing wounds by enabling rapid healing, which further supports the market growth.
Furthermore, research and development efforts have led to the introduction of innovative wound care biologics with enhanced efficacy and safety profiles. The introduction of novel growth factors, stem cell-based therapies, and tissue-engineered products have expanded the treatment options available, driving market growth. For instance, Organogenesis Holding Inc. company has developed and commercialized a product called Apligraf, which is an advanced tissue-engineered therapy designed for the treatment of chronic wounds. Such advanced products available in the market drive the market growth.
In addition, ongoing research in the field of regenerative medicine, exploring the potential of stem cells, growth factors, and tissue engineering to promote wound healing further support the market growth This surge in investment in research and development activities by pharmaceutical companies, academic institutions, and healthcare organizations has accelerated the discovery of novel therapeutic approaches, fueling the growth of the market.
The wound care biologics market is segmented on the basis of product, wound type, end user, and region. By product, the market is bifurcated into biological skin substitutes and topical agents. The biological skin substitutes segment further classified into human donor tissue derived products, animal derived products, and cell based bioengineered products. By wound type, the market is categorized into acute and chronic. The acute segment is further classified into burns & trauma, and surgical. The chronic segment is further divided into pressure ulcers, diabetic ulcers, venous ulcers, and others. By end user, the market is segregated into hospitals and clinics, wound centers and burn centers, and others. Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and rest of LAMEA).
Major key players that operate in the wound care biologics market are ConvaTec Group plc, Integra LifeSciences Holdings Corporation, Kerecis, Lavior Pharma Inc., MIMEDX Group, Inc., Organogenesis Holding Inc., Skye Biologics Holdings, LLC, Smith & Nephew plc, Stryker Corporation., Tissue Regenix Group Plc. Key players have adopted product launch, product approval, and acquisition as key developmental strategies to improve the product portfolio of the wound care biologics market.
The wound care biologics market has experienced significant growth owing to the increase in prevalence of chronic wounds, such as diabetic foot ulcers, venous leg ulcers, and pressure ulcers, which is a major factor that fosters the wound care biologics market growth. For instance, according to National Diabetes Statistics Report by Centers for Disease Control and Prevention (CDC), 2022, about 37.3 million people are diabetic in the U.S. As the number of people with diabetes continues to grow, so does the risk of developing diabetic foot ulcers, leading to higher demand for effective treatment options including wound care biologics.
In addition, elderly individuals are more prone to chronic wounds thus, the rise in geriatric population drives the demand for wound care biologics and propels market growth. These advanced therapies provide efficient wound healing to this vulnerable population. Moreover, traditional wound care products such as hydrocolloids, hydrogels, film & foam dressings, and alginates are being increasingly replaced with advanced wound care products such as biologics, due to their enhanced effectiveness in managing wounds by enabling rapid healing, which further supports the market growth.
Furthermore, research and development efforts have led to the introduction of innovative wound care biologics with enhanced efficacy and safety profiles. The introduction of novel growth factors, stem cell-based therapies, and tissue-engineered products have expanded the treatment options available, driving market growth. For instance, Organogenesis Holding Inc. company has developed and commercialized a product called Apligraf, which is an advanced tissue-engineered therapy designed for the treatment of chronic wounds. Such advanced products available in the market drive the market growth.
In addition, ongoing research in the field of regenerative medicine, exploring the potential of stem cells, growth factors, and tissue engineering to promote wound healing further support the market growth This surge in investment in research and development activities by pharmaceutical companies, academic institutions, and healthcare organizations has accelerated the discovery of novel therapeutic approaches, fueling the growth of the market.
The wound care biologics market is segmented on the basis of product, wound type, end user, and region. By product, the market is bifurcated into biological skin substitutes and topical agents. The biological skin substitutes segment further classified into human donor tissue derived products, animal derived products, and cell based bioengineered products. By wound type, the market is categorized into acute and chronic. The acute segment is further classified into burns & trauma, and surgical. The chronic segment is further divided into pressure ulcers, diabetic ulcers, venous ulcers, and others. By end user, the market is segregated into hospitals and clinics, wound centers and burn centers, and others. Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and rest of LAMEA).
Major key players that operate in the wound care biologics market are ConvaTec Group plc, Integra LifeSciences Holdings Corporation, Kerecis, Lavior Pharma Inc., MIMEDX Group, Inc., Organogenesis Holding Inc., Skye Biologics Holdings, LLC, Smith & Nephew plc, Stryker Corporation., Tissue Regenix Group Plc. Key players have adopted product launch, product approval, and acquisition as key developmental strategies to improve the product portfolio of the wound care biologics market.
Key Benefits For Stakeholders
- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the wound care biologics market analysis from 2022 to 2032 to identify the prevailing wound care biologics market opportunities.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the wound care biologics market segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report includes the analysis of the regional as well as global wound care biologics market trends, key players, market segments, application areas, and market growth strategies.
Additional benefits you will get with this purchase are:
- Quarterly update (only available with the purchase of an enterprise license)
- 5 additional company profiles of your choice, pre- or post-purchase, as a free update.
- Free updated version (once released) with the purchase of a 1-5 or enterprise user license.
- 16 analyst hours of support (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
- 15% free customization (in case the scope or segment of the report does not match your requirements, 20% is equivalent to 3 working days of free work, applicable once)
- Free data pack (Excel version) with the purchase of a 1-5 or enterprise user license.
- Free report update, if the report is 6-12 months old or older.
- 24-hour priority response
- Free industry updates and white papers.
Key Market Segments
By Wound Type
- Acute Wound
- Type
- Burns and Trauma
- Surgical
- Chronic Wound
- Type
- Pressure Ulcer
- Diabetic Ulcer
- Venous Ulcer
- Others
By End User
- Hospitals and Clinics
- Wound Centers and Burn Centers
- Others
By Product
- Biological Skin Substitutes
- Type
- Human Donor Tissue Derived Products
- Animal Derived Products
- Cell Based Bioengineered Products
- Topical Agents
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
Key Market Players
- Skye Biologics Holdings, LLC
- Tissue Regenix Group Plc
- Lavior Pharma Inc.
- ORGANOGENESIS HOLDINGS INC.
- Kerecis
- Smith & Nephew plc
- Stryker Corporation.
- MIMEDX Group, Inc.
- Integra LifeSciences Holdings Corporation
- ConvaTec Group plc
Please note:
- Online Access price format is valid for 60 days access. Printing is not enabled.
- PDF Single and Enterprise price formats enable printing.
Table of Contents
CHAPTER 1: INTRODUCTION
CHAPTER 2: EXECUTIVE SUMMARY
CHAPTER 3: MARKET OVERVIEW
CHAPTER 4: WOUND CARE BIOLOGICS MARKET, BY PRODUCT
CHAPTER 5: WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE
CHAPTER 6: WOUND CARE BIOLOGICS MARKET, BY END USER
CHAPTER 7: WOUND CARE BIOLOGICS MARKET, BY REGION
CHAPTER 8: COMPETITIVE LANDSCAPE
CHAPTER 9: COMPANY PROFILES
List of Tables
List of Figures
Executive Summary
The Wound Care Biologics Market is likely to experience a significant growth rate of 6.1% from 2023-2032 owing to increase in demand for wound care biologics and increase in research and developmwnt activites from pharmaceutical sector. According to this report, the wound care biologics market was valued at $1.8 billion in 2022, and is estimated to reach $3.3 billion by 2032, growing at a CAGR of 6.1% from 2023 to 2032. Wound care biologics refers to development and production of advanced therapeutic products derived from living organisms or their components. These biologic products are specifically designed to promote wound healing, tissue regeneration, and the management of complex or chronic wounds. Wound care biologic products enable faster healing due to their efficiency & effectiveness in managing wounds.
Key factors driving the growth of the wound care biologics market include the rise in burden of burn injuries such as road accidents, sport injuries, burn accidents, and trauma events, fosters the demand for wound care biologics products such as gels, ointments and creams, and skin substitutes. In addition, an increase in incidences of chronic diseases such as diabetes, rise in incidence of burn injury, and the surge in prevalence of chronic wounds such as foot ulcers, are expected to drive the growth of the wound care biologics market. Futhermore, the rise in geriatric population and it is a significant risk factor for diseases drive the market growth. The aging population is prone to chronic wounds due to age related factors. Rise in geriatric population led to increase in demand for wound care biologics to promote faster and more effective wound healing.
Moreover, ongoing advancements in wound care management propel market growth. In addition, bioengineered skin substitutes are innovative products that are used in ulcer treatment to promote wound healing. These substitutes consist of living cells, synthetic materials, or a combination of both. They may provide a scaffold for cell growth, enhance tissue regeneration, and accelerate wound closure. Examples include acellular dermal matrices, cultured epidermal autografts, and bilayer bioengineered skin substitutes. For instance, the introduction of InnovaMatrix PD by Triad Life Sciences company is an innovative advancement in the management of wounds.
The market also offers growth opportunities to the key players in the market. Emerging markets, including countries in Asia-Pacific, Latin America, and Africa, have experienced rapid economic growth, owing to increased healthcare spending, and surged demand for healthcare products and services. These factors drive the growth of the wound care biologics market in these regions. In addition, emerging markets often experience diabetes and obesity. These chronic diseases contribute to the development of chronic wounds, which require specialized wound care treatments. Thus, the surge in prevalence of chronic diseases provides a lucrative opportunity for market growth.
The wound care biologics market is segmented into product, wound type, end user and region. On the basis of drug class, the market is categorized into biological skin substitutes and topical agents. The biological skin substitutes segment further classified into human donor tissue derived products, animal derived products, and cell based bioengineered products. On the basis of wound type, the market is categorized into acute and chronic. The acute segment is further classified into burns & trauma, and surgical. The chronic segment is further divided into pressure ulcers, diabetic ulcers, venous ulcers, and others.
On the basis of distribution channel, it is segregated into end user, the market is segregated into hospitals and clinics, wound centers and burn centers, and others. Region wise, it is analyzed across North America (the U. S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific ((Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
The key players profiled in the study include ConvaTec Group plc, Integra LifeSciences Holdings Corporation, Kerecis, Lavior Pharma Inc., MIMEDX Group, Inc., Organogenesis Holding Inc., Skye Biologics Holdings, LLC, Smith & Nephew plc, Stryker Corporation., Tissue Regenix Group Plc. The players in the market have been actively engaged in the adoption various strategies such as a product launch, product approval, and acquisition to remain competitive and gain advantage over the competitors in the market. For instance, in December 2022, MiMedx Group, Inc., a leader in placental biologics announced agreement with Turn Therapeutics. This agreement provides MIMEDX with exclusive rights to Turn's PermaFusion proprietary antimicrobial intellectual property (IP) and utilize the PermaFusion platform in the development of future biologic products, with a specific focus on applications related to wound healing and surgical recovery.
Key Market Insights
By product, the biological skin substitutes segment was the largest revenue contributor to the market and is estimated to reach $2.80 billion by 2032, with a highest CAGR of 6.3%.By wound type, the chronic wound segment dominated the global market with a highest CAGR of 6.3% during the forecast period.
Based on end user, the hospitals and clinics segment was the largest revenue contributor to the market and with a highest CAGR of 6.7% during the forecast period.
Based on region, North America garnered the largest revenue share in 2022, whereas Asia-Pacific is anticipated to grow at the highest CAGR during the forecast period.
Companies Mentioned
- Skye Biologics Holdings, LLC
- Tissue Regenix Group Plc
- Lavior Pharma Inc.
- ORGANOGENESIS HOLDINGS INC.
- Kerecis
- Smith & Nephew plc
- Stryker Corporation.
- MIMEDX Group, Inc.
- Integra LifeSciences Holdings Corporation
- ConvaTec Group plc
Methodology
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.
LOADING...
